Malignant arrhythmias in relation to values of serum potassium in patients with acute myocardial infarction.
The relationship between levels of potassium in the serum and the development of malignant arrhythmias was examined in a retrospective study involving 1011 patients presenting with acute myocardial infarction. Thirteen percent of the overall patients studied had significant hypokalemia (k less than 3.5 mmol/liter). The average initial level of potassium in patients who developed malignant arrhythmias was (4.10 mmol/liter) significantly lower (P less than 0.01) than those patients who did not develop such arrhythmias (4.19 mmol/liter). To determine whether the level of potassium was, in itself, the primary cause of malignant arrhythmias following myocardial infarction, a subgroup analysis of factors influencing these levels was performed. It was determined that diabetics have a higher level of potassium than nondiabetics (4.2 mmol/liter versus 4.11 mmol/liter - P = 0.01) and a lower incidence of malignant arrhythmias (50.5% versus 63.5% - P = 0.002). No correlation was found between treatment with either digitalis or diuretics and malignant arrhythmias. Size and location of infarcted areas was found to have a direct relationship with development of arrhythmias. Size and location of infarctions, however, were not found to be related to levels of potassium in the serum. Our findings support and clarify earlier suggestions establishing the levels of potassium in the serum as an important causative factor, together with size and location of infarctions, in the development of malignant arrhythmias.
Heart Institute, Assaf Harofeh Medical Center, Zerifin, Israel.
A
A
Friedensohn
H E
HE
Faibel
O
O
Bairey
U
U
Goldbourt
Z
Z
Schlesinger
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000097:blood / Q000209:etiology*; D003920:Diabetes Mellitus / Q000097:blood; D004077:Digoxin / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D006327:Heart Block / Q000097:blood / Q000209:etiology; D006706:Homeostasis; D006801:Humans; D006947:Hyperkalemia / Q000097:blood; D007008:Hypokalemia / Q000097:blood; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000473:pathology; D011188:Potassium / Q000097:blood*; D012189:Retrospective Studies; D013610:Tachycardia / Q000097:blood / Q000209:etiology; D014693:Ventricular Fibrillation / Q000097:blood / Q000209:etiology
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D004232:Diuretics; D004077:Digoxin; D011188:Potassium